Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)

NCT06959784 · clinicaltrials.gov ↗

PHASE4

Phase

ENROLLING_BY_INVITATION

Status

142

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus
Cardiovascular Diseases
Cerebrovascular Disease

Interventions

DRUG: semaglutide
DRUG: Metformin

Sponsor

China-Japan Friendship Hospital